Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

11 Customer Reviews

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

    HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

  • U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NV34OXpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn6NZYxNTFyIN88US=> NIfz[WYxNTRiZB?= MlvXbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYfPeW8zOjZ5MEK3PFQ>
HepG2 M{[4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrkNE0yOCEQvF2= MlrINE01KGR? NUiwTZc4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NV7iXFNCOjZ5MEK3PFQ>
HT29 MlP1SpVv[3Srb36gRZN{[Xl? NV3OT5RlPTEEoH7N MonLNlQuPzJiaB?= NWPFNm5VcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB2ONMgbOKh NV3wVYF4OjZ5MEK3PFQ>
HepG2 MWjGeY5kfGmxbjDBd5NigQ>? NGLFVpk2OMLibl2= MWCyOE04OiCq NX25RlJvcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB{NNMgbOKh MkHoNlY4ODJ5OES=
HCC827 NFnWclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvROU84NjVxMUCgcm0> MmeyO|LDqGh? MWjEUXNQ NFq0fHBmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= Mkm4NlY3PzV2OES=
A549  NWr3VYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYKxNE8yPS9{MDDuUS=> Ml[0O|LDqGh? NF\yZVJFVVOR MkfM[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? M4HY[|I3Pjd3NEi0
NCI-H460  M3zzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DxUlExNzJyL{OwJI5O MVW3NuKhcA>? NF7USZhFVVOR NHr6UpRmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= NGfKWWwzPjZ5NUS4OC=>
J89GFP MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3EUXNQyqB? NIfEdplGSzVyPUS5Mlg2KMLzIEGyMlY2KG6P NIL5[YUzPjV4M{W2PC=>
THP89GFP M4HxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j0PWROW00EoB?= NYixT2hxTUN3ME2xPU4{PCEEsTC2MlQ{KG6P NHHDcnEzPjV4M{W2PC=>
SK-NEP-1 MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PSVVAvODIkgKOxNE4xKM7:TR?= MWGyOEBp NWLTVoUyTE2VT9Mg Ml7uTWM2OD15Nj6zOEBvVQ>? NUjPc|I1OjZzN{[yNVk>
G401 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHxNE4xOeLCk{GwMlAh|ryP M2jDSVI1KGh? NX3KOGtMTE2VT9Mg MkHDTWM2OD1zNEOuNFIhdk1? Ml\ONlYyPzZ{MUm=
SK-NEP-1 MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3HSRlUxKG6P NUXleXVMOeLCk{Sg[C=> NVXzc2l6TE2VT9Mg NEXJXZNz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? M3PTRlI3OTd4MkG5
G401 NIT3[m5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVK1NEBvVQ>? NXniNJJ3OeLCk{Sg[C=> NIO0N3pFVVORwrC= NHvXWIpz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? Mom4NlYyPzZ{MUm=
SK-NEP-1 NXXmRpRJSXCxcITvd4l{KEG|c3H5 MW[1NE8yODBibl2= Mm\CNlQhcA>? NVfRTY9GTE2VT9Mg NIHCZ3ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NF;COlIzPjF5NkKxPS=>
G401 MmfORZBweHSxc3nzJGF{e2G7 NHLJWY82OC9zMECgcm0> MoHJNlQhcA>? NYfnOmUyTE2VT9Mg Ml\abY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGXRfVMzPjF5NkKxPS=>
SK-NEP-1 NYHJZVFbTnWwY4Tpc44hSXO|YYm= NWDx[5hoPTBxMUCwJI5O NVvMfXJDOjRiaB?= NGfo[lhFVVORwrC= NFnudZh{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w NUOzN|N6OjZzN{[yNVk>
G401 M2KzemZ2dmO2aX;uJGF{e2G7 M4\QOlUxNzFyMDDuUS=> M4LkO|I1KGh? MYTEUXNQyqB? MmPCd4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? MXuyOlE4PjJzOR?=
SK-NEP-1 M{nHZmZ2dmO2aX;uJGF{e2G7 NVLF[FNIPTBxMUCwJI5O MXqyOEBp M4Da[2ROW00EoB?= M1zT[olv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh NFHYO44zPjF5NkKxPS=>
G401 NHfIbItHfW6ldHnvckBCe3OjeR?= MkLyOVAwOTByIH7N NUHtPYpxOjRiaB?= NEKyeI1FVVORwrC= MkflbY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> M4rNZlI3OTd4MkG5
RPMI 8226 MkD5R4VtdCCVdYL2bZZidCCDc4PhfS=> NVjX[45KOi92L{[gcm0> MmHaOFjjiImq MmTsbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? MWKyOlAxODJ7Mh?=
OPM2 M3vlUmNmdGxiU4Xyeol3[WxiQYPzZZk> NF7RUIIzNzRxNjDuUS=> NXnBcmd5PDkkgJno NFLnXIxqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NXTieI91OjZyMECyPVI>
U266 NV7vW|I4S2WubDDTeZJ3cX[jbDDBd5NigQ>? MkTRNk81NzZibl2= MmXQOFjjiImq Mm\wbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? MV2yOlAxODJ7Mh?=
H929 NFfSSYRE\WyuIGP1dpZqfmGuIFHzd4F6 NGS2enUzNzRxNjDuUS=> NF3MR2I1QOLCiXi= MV3pcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp MkHONlYxODB{OUK=
RPMI 8226  NYq4W5JQSXCxcITvd4l{KEG|c3H5 MV:05qCKdk1? NHS3V4gzPC92ODDo M4HRPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MorGNlYxODB{OUK=
HCC827 NIe4d2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXtN2M3OTBibl2= NGP1c|Q1QCCq NX:5N2JDTE2VTx?= NYD5SIdb\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= MXKyOVk1PDZzNx?=
NCI-H23 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKxNEBvVQ>? M3\4VFQ5KGh? MUfEUXNQ MYnlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? MmrFNlU6PDR4MUe=
AML3 MnG1SpVv[3Srb36gRZN{[Xl? NVX4eFVkOC1zIN88US=> NH7QUpgzPMLiaB?= MVzpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoPQNlU3OTJ7NEG=
ML-1 M3X6N2Z2dmO2aX;uJGF{e2G7 NY\pem1SOC1zIN88US=> M2\QU|I1yqCq NH7nRmhqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYWyOVYyOjl2MR?=
RPMI-8226vr10  NHvYVFVHfW6ldHnvckBCe3OjeR?= NWCwfHVqOC1zIN88US=> MYKyOOKhcA>? NWTKNnNVcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVS2THc1OjV4MUK5OFE>
ML-1 MXnGeY5kfGmxbjDBd5NigQ>? MUKxJO69VQ>? NE\MVG4zPMLiaB?= NFG4e5pqdmO{ZXHz[ZMh[2G|cHHz[U0{KGGldHn2bZR6KDRvZn;s[C=> MkfsNlU3OTJ7NEG=
RPMI-8226vr10  M{\MPWZ2dmO2aX;uJGF{e2G7 MVqxJO69VQ>? MWKyOOKhcA>? MXHpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFIvPS2ob3zk M3TKWVI2PjF{OUSx
SK-N-BE (2) MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYeyOQKBkWh? MWnJR|UxRTFyND6w5qCKyrIkgJm3Mlghdk1? MW[yOVMxQDlzNh?=
SK-N-BE (2), PAN  MK Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ziWlI16oDLaB?= NIOybFJKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= NEm2V2QzPTNyOEmxOi=>
SK-N-BE (2), MK  PAN MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljyNlTjiImq Mlm5TWM2OD1|OEKuNQKBkcLz4pEJOFMvOiCwTR?= Mmm2NlU{ODh7MU[=
SK-N-AS NGPwfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7KNlTjiImq NXv6c3BIUUN3ME2zO{4y6oDLwsJihKkzNjRibl2= MXOyOVMxQDlzNh?=
SK-N-DZ M4XYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPxT4ozPOLCiXi= M3XkUGlEPTB;MUeuNgKBkcLz4pEJNE41KG6P NYS5emx6OjV|MEi5NVY>
Caki-1 NILHfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnHRXpYOTBxMkWvOVAhdk1? M1GzXlQ5KGh? MnHYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ NFv6Z5QzPTJ5OUG5NS=>
ACHN NF;5c4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\LXFExNzJ3L{WwJI5O Mmn1OFghcA>? NHHFTIJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MoqxNlUzPzlzOUG=
769-P NYrZNItnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7MbY0zOTBxMkWvOVAhdk1? M2C3TFQ5KGh? M{e4RolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= NYXQVmdYOjV{N{mxPVE>
786-O  M4O1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXoNVAwOjVxNUCgcm0> M{Pm[|Q5KGh? NGHsOohqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MViyOVI4QTF7MR?=
Caki-1 NX3hVlR2SXCxcITvd4l{KEG|c3H5 Ml\1OVAhdk1? MUK0PEBp NFuzVZVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= Ml7BNlUzPzlzOUG=
ACHN NXj3b2t1SXCxcITvd4l{KEG|c3H5 NGK0[Zg2OCCwTR?= MWG0PEBp MlLMbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? Mn\VNlUzPzlzOUG=
769-P MWHBdI9xfG:|aYOgRZN{[Xl? MXK1NEBvVQ>? MVW0PEBp MXPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? NWT1NIRZOjV{N{mxPVE>
786-O  NFXhdFNCeG:ydH;zbZMhSXO|YYm= MlnWOVAhdk1? MUe0PEBp M{nKT4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ MljvNlUzPzlzOUG=
Caki-1 NULQOY1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHINlUwPTBibl2= NUPmeVlGPDhiaB?= MnvVSG1UVw>? MYjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MVuyOVE4PjN3NB?=
ACHN NITYdotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjZeFFYOjVxNUCgcm0> MUC0PEBp MV\EUXNQ NXrl[ZZocW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> MW[yOVE4PjN3NB?=
769-P NFPscZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe2dnZPOjVxNUCgcm0> Mn;xOFghcA>? MV;EUXNQ NXXqR4ticW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> MV[yOVE4PjN3NB?=
Caki-1 MlXOR49td267IF\vdo1ifGmxbjDBd5NigQ>? M{Pud|UxKG6P NG\1OZU4NTF2IHS= NVPvfm9yTE2VTx?= MkOxd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> Mm[4NlUyPzZ|NUS=
ACHN NFSzR49Ed2yxbomgSo9zdWG2aX;uJGF{e2G7 M4LaUFUxKG6P MWO3MVE1KGR? NVKzcHEzTE2VTx?= M{f1fZN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh M3\WNFI2OTd4M{W0
769-P NUDhSWhnS2:ub375JGZwem2jdHnvckBCe3OjeR?= M37WWVUxKG6P NXrHR3hOPy1zNDDk NXnUNXpsTE2VTx?= MVnzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> M{\kTlI2OTd4M{W0
Caki-1 NEjHVI5CeG:ydH;zbZMhSXO|YYm= MoLQOVAhdk1? M{HsXlQ5KGh? NVPldJhlTE2VTx?= NF;YT3FqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MonvNlUyPzZ|NUS=
ACHN M1voOWFxd3C2b4Ppd{BCe3OjeR?= NEXqeng2OCCwTR?= M1fBc|Q5KGh? MYPEUXNQ M3TGTolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3fl[VI2OTd4M{W0
769-P NWG3RmVZSXCxcITvd4l{KEG|c3H5 NHrlblg2OCCwTR?= NITEPGI1QCCq MVnEUXNQ NGOxZnBqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MkGyNlUyPzZ|NUS=
MDA-MB-231 MmDIUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 M3jIfVExyqCwTR?= MVmzxsBl NWLBfGNRTE2VTx?= MUThcJRmenNiY3XscEBud3KyaH;sc4d6yqB? MX:yOFgyODR7Nx?=
BT-549 NUDUdGJbVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 MkfsNVDDqG6P MXizxsBl MkmwSG1UVw>? M3jNXYFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= NFewZlQzPDhzMES5Oy=>
MCF-7  MmHSUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 MnTmNVDDqG6P NXzDXXVRO8LiZB?= NVS5[GRmTE2VTx?= NFjCPHpidHSncoOgZ4VtdCCvb4LwbI9td2e7wrC= NF[5NZMzPDhzMES5Oy=>
MCF-7 NFXXNFBHfW6ldHnvckBCe3OjeR?= MVu1MVUxKG6P MlXNNlQhcA>? MkH2SG1UVw>? NFjt[nhz\WS3Y3XkJJRp\SCuZY\lcEBw\iCneIDy[ZN{cW:wIH;mJGVT|rFuIGDSJIFv\CCIb4jBNeKh MlGyNlQ{PjZ2MEe=
CTS MV3BdI9xfG:|aYOgRZN{[Xl? MkDiNQKBmzRyIH7NxsA> NXzrT4JvPDhiaB?= MX;pcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NX3w[JFlOjR{NES0Nlk>
OCI-AML3  M3nEXWFxd3C2b4Ppd{BCe3OjeR?= MX2w5qCUPDBibl5CpC=> NEX0Sog1QCCq MVvpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHLIZWMzPDJ2NESyPS=>
U937 MX3BdI9xfG:|aYOgRZN{[Xl? NHvsWoYx6oDVNECgcm3DqA>? NUjxfIRwPDhiaB?= MoTpbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3KwTVI1OjR2NEK5
PC3 NYrmO|FXSXCxcITvd4l{KEG|c3H5 MkC4NE0yODBibl2= MnP3NlQwPDhiaB?= MX3pcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mk\GNlQyPjN{M{C=
PC3-AR MWHBdI9xfG:|aYOgRZN{[Xl? NXLyb243OC1zMECgcm0> MVOyOE81QCCq MVHpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXeyOFE3OzJ|MB?=
PC3 NYL4cGR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXlNE0yODBibl2= NH74THczPC92ODDo M1HmUolv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25? MXGyOFE3OzJ|MB?=
PC3-AR MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYewMVExOCCwTR?= M13S[VI1NzR6IHi= Mn3mbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckB1cGViR{LNJJBp[XOn MXKyOFE3OzJ|MB?=
PC3 NUDafodNTnWwY4Tpc44hSXO|YYm= Mo[wNE0yODBibl2= NUTvfXZ3OjRiaB?= Ml[zd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= NUHROWc6OjRzNkOyN|A>
PC3-AR NHXxVGZHfW6ldHnvckBCe3OjeR?= MkO2NE0yODBibl2= NETxd|YzPCCq MX\zeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= NYrEZ4psOjRzNkOyN|A>
OS-RC-2 MlXQR4VtdCCYaXHibYxqfHliQYPzZZk> Mlu5NE0yODByIH7N M2O5SVI1NzR6L{eyJIg> MWnEUXNQ MWTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NIXrVXQzPDF2NEezOy=>
OS-RC-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX21NEBvVQ>? MU[0PEBp NGfSfolFVVOR M{\lc4lv\HWlZYOgS|IwVSCjcoLld5Q> M2LBZVI1OTR2N{O3
OS-RC-2 NWP1dnVqSXCxcITvd4l{KEG|c3H5 MmfCOVAhdk1? M4DGc|Q5KGh? NWG3bFNMTE2VTx?= MXrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M1;DV|I1OTR2N{O3
SK-N-AS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnpNQKBmzhyIH7N Ml;0OFghcA>? MWLJR|UxRTJ5LkSgcm0> M{DxU|I1ODl6N{m5
SK-N-DZ NITJ[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XuV|DjiJN6MDDuUS=> NHLy[pI1QCCq NFj0bIxKSzVyPUKxMlkhdk1? Mk\GNlQxQTh5OUm=
SK-N-SH MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSw5qCUQDBibl2= M2HPR|Q5KGh? MWnJR|UxRTd{LkOgcm0> MXWyOFA6QDd7OR?=
SK-N-BE MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nKdlDjiJN6MDDuUS=> NFXUeXY1QCCq NVTaXopOUUN3ME23OU41KG6P M133XFI1ODl6N{m5
SK-N-AS NVLnR2VrSXCxcITvd4l{KEG|c3H5 MWmw5qCUQDBibl2= NGPxSHQ1QCCq MlvQdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u M2e0UVI1ODl6N{m5
SK-N-DZ NUnZO5hbSXCxcITvd4l{KEG|c3H5 NXLQfI9OOOLCk{iwJI5O M{XOZlQ5KGh? NF76WGVxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> NYn4eWI1OjRyOUi3PVk>
SK-N-SH MXTBdI9xfG:|aYOgRZN{[Xl? MViw5qCUPDBibl2= NXfDRnJnPDhiaB?= NFfrTHBxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> MXKyOFA6QDd7OR?=
SK-N-BE Mn\JRZBweHSxc3nzJGF{e2G7 NFvVZoMx6oDVNECgcm0> Moq5OFghcA>? MVTwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= MknSNlQxQTh5OUm=
SK-N-AS M2ruNGZ2dmO2aX;uJGF{e2G7 MofyNQKBmzhyIH7N NITVPZM1QCCq MoDMbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> NW\xOmV7OjRyOUi3PVk>
SK-N-DZ M3PqemZ2dmO2aX;uJGF{e2G7 MkKwNQKBmzhyIH7N NUfQSI1vPDhiaB?= NX;0WGs3cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? NX60[oVTOjRyOUi3PVk>
SK-N-SH NEDsTI1HfW6ldHnvckBCe3OjeR?= NV3lbndWOOLCk{SwJI5O NF7VN2I1QCCq NIjlNoVqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR Mn\PNlQxQTh5OUm=
SK-N-BE MmTRSpVv[3Srb36gRZN{[Xl? MViw5qCUPDBibl2= MVW0PEBp MY\pcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ NXLXXmhvOjRyOUi3PVk>
HCC-LM3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;GT|EuOTByMDDuUS=> MUKyOE81QC95MjDo MmHZSG1UVw>? MkmybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{nuVlI1ODl|OUW2
HepG2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvqNU0yODByIH7N NWD5N5hvOjRxNEivO|IhcA>? MYPEUXNQ M2jIfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmPGNlQxQTN7NU[=
SMMC-7721 NGf1NoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rRN|EuOTByMDDuUS=> NIfSOHEzPC92OD:3NkBp NXHtS4ZsTE2VTx?= MmqzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3WyVFI1ODl|OUW2
HCC-LM3 M1XiS2Fxd3C2b4Ppd{BCe3OjeR?= Mnz6OVAhdk1? NHnqOJA1QCCq M2PvcGROW09? M3fvVIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 NV;zZ49ROjRyOUO5OVY>
HepG2 M4fufmFxd3C2b4Ppd{BCe3OjeR?= NWTnbYdpPTBibl2= M1vTUFQ5KGh? NHv6NGdFVVOR MmX1bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> NXjJcZp3OjRyOUO5OVY>
SMMC-7721 MVnBdI9xfG:|aYOgRZN{[Xl? MV61NEBvVQ>? NWLTXFVkPDhiaB?= MlfDSG1UVw>? NY[zfYZ3cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? M33lbVI1ODl|OUW2
HCC-LM3 NF:x[WhHfW6ldHnvckBCe3OjeR?= M2mzVVUxNzFyMDDuUS=> Mn\tNlQhcA>? MYfEUXNQ NHTLWJBl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg MViyOFA6Ozl3Nh?=
HepG2 M{nCfWZ2dmO2aX;uJGF{e2G7 MlTiOVAwOTByIH7N NV;3PVJpOjRiaB?= M4jLTGROW09? MoPk[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= Mor2NlQxQTN7NU[=
SMMC-7721 MW\GeY5kfGmxbjDBd5NigQ>? MkPxOVAwOTByIH7N Mo\qNlQhcA>? NYWyNnNSTE2VTx?= M3vnSIRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= MnvINlQxQTN7NU[=
HCC-LM3 M3zPXWZ2dmO2aX;uJGF{e2G7 NILDc3Y2OC9zMECgcm0> MVqyOEBp NVftOZo6TE2VTx?= M4TOXIRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? M3;rOVI1ODl|OUW2
HepG2 NYLzRmlXTnWwY4Tpc44hSXO|YYm= MUe1NE8yODBibl2= Ml;uNlQhcA>? M4WyO2ROW09? NF3SfnBld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w NGr1SGozPDB7M{m1Oi=>
SMMC-7721 MoKwSpVv[3Srb36gRZN{[Xl? NGKwcXA2OC9zMECgcm0> NF3EcZkzPCCq M3:1c2ROW09? NEXnRY9ld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w MnnBNlQxQTN7NU[=
FaDu NVXncVYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxNFDjiIWwTR?= MXy4M|ExNzF{IHi= MXrkbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V? MnfSNlQxOjZ2OEK=
FaDu M{C3dmZ2dmO2aX;uJGF{e2G7 NIXHNXgyODEkgJXuUS=> M13Jd|IwPC96L{GyJIg> MmnibY5lfWOnZDDwNlFY[WZzL1PpdFHDqGW6cILld5Nqd25? NGHnOpUzPDB{NkS4Ni=>
PC-3  MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rLSVAuOTBizszN NUSxZXlbOjRxNEivO|IhcA>? NYjB[XRWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MorpNlM6QTF{MU[=
LNCaP MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrNemIxNTVizszN Mmm0NlQwPDhxN{KgbC=> Ml7jbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGradIgzOzl7MUKxOi=>
RWPE-1  MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS1RpdJOC1{MDFOwG0> MXeyOE81QC95MjDo MoL1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3LL[lI{QTlzMkG2
Capan-1 M33PVWZ2dmO2aX;uJGF{e2G7 MX[yOU82OC9zMECgcm0> MXK4M|I1NzR6IHi= MoLESG1UVw>? NWrzcWFH\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> M4nhSFI{QTJ{OEi2
L3.6pl M3n3XWZ2dmO2aX;uJGF{e2G7 M4m5[FI2NzVyL{GwNEBvVQ>? MkX5PE8zPC92ODDo MmflSG1UVw>? MV7kc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p MlnUNlM6OjJ6OE[=
CFPAC-1  NFTPbXRHfW6ldHnvckBCe3OjeR?= NXPPbVFkOjVxNUCvNVAxKG6P NXTsTI9IQC9{ND:0PEBp MUTEUXNQ NXe3U5pk\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> NV\HSIlVOjN7MkK4PFY>
Capan-1 NI\kOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXJNlUwPTBxMUCwJI5O NGDj[Zk1QCCq NUnBVpA5TE2VTx?= NV3YT3Q5emWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MkHYNlM6OjJ6OE[=
L3.6pl MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu5NlUwPTBxMUCwJI5O M{Hxd|Q5KGh? NIjOT4pFVVOR MUDy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGS5[mMzOzl{Mki4Oi=>
CFPAC-1  NUPtfVhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGyOU82OC9zMECgcm0> NUXMN2w1PDhiaB?= MoPJSG1UVw>? NVLkelRsemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWCyN|kzOjh6Nh?=
Capan-1 NWTSOWd2SXCxcITvd4l{KEG|c3H5 MUKyOU82OC9zMECgcm0> M2fiOFQ5KGh? NHfjWHhFVVOR NFXxSJNqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MoDxNlM6OjJ6OE[=
L3.6pl M37ORmFxd3C2b4Ppd{BCe3OjeR?= MYqyOU82OC9zMECgcm0> NX3qXWd7PDhiaB?= M{O4NGROW09? NVK2V3pMcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWGyN|kzOjh6Nh?=
CFPAC-1  MWjBdI9xfG:|aYOgRZN{[Xl? MlzSNlUwPTBxMUCwJI5O MoK1OFghcA>? MUjEUXNQ MYLpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUSyN|kzOjh6Nh?=
HN22 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSwMVIxKG6P NWDGblg3OjRxNEigbC=> Mo\CSG1UVw>? Moi0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> Mn7vNlM5Pzd{M{W=
HSC4  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVuySYhpOC1{MDDuUS=> NHfGWmszPC92ODDo NXPJcoltTE2VTx?= NYTtWZJ7cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? M1qwTlI{QDd5MkO1
HN22 Mn7CRZBweHSxc3nzJGF{e2G7 MUOwMVIxKG6P NFvvNG01QCCq MYfEUXNQ M17pTolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3frXlI{QDd5MkO1
HSC4  M2nnRmFxd3C2b4Ppd{BCe3OjeR?= MWKwMVIxKG6P MYK0PEBp MWTEUXNQ NFfBSoRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NUPYSohzOjN6N{eyN|U>
HN22 MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGydmpOOC1{MDDuUS=> M2DlSVQ5KGh? NVP3c3pOTE2VTx?= NU[2eGw2cW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh NY\iUGxpOjN6N{eyN|U>
HSC4  NEHydHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TQVVAuOjBibl2= NUTCeGxVPDhiaB?= M1LZNGROW09? NV;5T3pLcW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh M1LjdlI{QDd5MkO1
HN22 MknFSpVv[3Srb36gRZN{[Xl? MnHaNE0zOCCwTR?= MoHZOFghcA>? MVrEUXNQ Mle4d5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg NH7H[JEzOzh5N{KzOS=>
HSC4  NWHDc|E{TnWwY4Tpc44hSXO|YYm= NVfVUncxOC1{MDDuUS=> M3TxclQ5KGh? NWXJOpdTTE2VTx?= Mn2zd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg M1nHdlI{QDd5MkO1
Cal62 NGG5TndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDIdpBKSzVyPUOzJOKyKDRibl2= M1[1NlI{QDJ2ME[0
Hth7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF3INMxJFIhdk1? M3u4SVI{QDJ2ME[0
Hth83 M3\4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTN2INMxJFUhdk1? MnrsNlM5OjRyNkS=
C643 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfKTWM2OD15MTFCtUAyOCCwTR?= NUjYVXhsOjN6MkSwOlQ>
SW1736 M1HwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{mydWlEPTB;M{WgxtEhQCCwTR?= NEPuepAzOzh{NEC2OC=>
T241 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTZ3INMxJFchdk1? NWPjOZpvOjN6MkSwOlQ>
T351 NIPscplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrhc|dKSzVyPUWwJOKyKDFyIH7N M4rxflI{QDJ2ME[0
BHP2-7 M{S5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXmwOW05UUN3ME2zO{DDuSB4IH7N MYCyN|gzPDB4NB?=
T238 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFuNUCwJOKyKDJyMDDuUS=> NWDRW4tFOjN6MkSwOlQ>
HCT8 MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm4Xm5xPzJiaB?= Mk\lSG1UVw>? MWDJR|UxRTF{LkpihKnDueLCiUGuPUBvVQ>? M4PnO|I{Ojl7M{i4
H630 M{mwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPvUHQ4OiCq NIPReYlFVVOR M3u1cWlEPTB;MUKuOQKBkcLz4pEJN{4yKG6P Ml7PNlMzQTl|OEi=
cH630 5-FU-res M3;FbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvQbJM4OiCq MULEUXNQ MWDJR|UxRTF3LkZihKnDueLCiUGuNkBvVQ>? MnTTNlMzQTl|OEi=
HCT116 M{fxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jmSVczKGh? M13R[2ROW09? MmXMTWM2OD1zMD635qCKyrIkgJmyMlIhdk1? MnXqNlMzQTl|OEi=
HCT116 p53−/− MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjNO|IhcA>? M3TySWROW09? MUHJR|UxRThwNvMAjeKy6oDLMT63JI5O MkPFNlMzQTl|OEi=
dHCT116 p21−/− M1qwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLVSWVwPzJiaB?= MYTEUXNQ NGK5SpZKSzVyPUWuPgKBkcLz4pEJNU4{KG6P MkDVNlMzQTl|OEi=
HT29 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS2O|IhcA>? NEnse3hFVVOR NUTBWGtqUUN3ME2xOk4{6oDLwsJihKkzNjNibl2= MoWyNlMzQTl|OEi=
LoVo MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXHd5E4OiCq NHH1U5hFVVOR MUjJR|UxRTVwMfMAjeKy6oDLMD62JI5O MnvINlMzQTl|OEi=
RKO NEnTVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvyPGY4OiCq M3\2cWROW09? M37u[mlEPTB;Nz655qCKyrIkgJmyMlIhdk1? M3;FfVI{Ojl7M{i4
SW480 M{LQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K4ZlczKGh? NGrh[IxFVVOR M2nTUGlEPTB;MUeuOgKBkcLz4pEJNE45KG6P M2fmRVI{Ojl7M{i4
eSW620 M{XLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHGUlZ6PzJiaB?= NIf0[nRFVVOR MorqTWM2OD17LkJihKnDueLCiUKuNUBvVQ>? NFT0e5MzOzJ7OUO4PC=>

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02802163 Not yet recruiting Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen April 30, 2017 Phase 1|Phase 2
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT02890069 Recruiting Colorectal Cancer|Non-small Cell Lung Carcinoma (Adenocarcinoma)|Triple Negative Breast Cancer Novartis Pharmaceuticals|Novartis October 26, 2016 Phase 1
NCT01802879 Active, not recruiting Hematologic Neoplasms Novartis Pharmaceuticals|Novartis June 24, 2013 Phase 2
NCT00532675 Active, not recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 22, 2008 Phase 1
NCT02961816 Not yet recruiting Lymphoma M.D. Anderson Cancer Center February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID